CorMedix to acquire Heron Therapeutics assets for $145M cash, stock and earn-outs

CorMedix Therapeutics has entered into a definitive asset purchase agreement to acquire substantially all assets of Heron Therapeutics for $145 million in cash plus about 14.6 million CorMedix shares, roughly $222.6 million total, plus potential earn-out payments. The deal adds four commercial medicines: ZYNRELEF, APONVIE, CINVANTI and SUSTOL. Moelis & Company is acting as exclusive financial and financing advisor to CorMedix.

Detected & updated continuously · Source: Nebula